With the introduction of the dual-use hybrid OI/CT modality, MILabs redefines how researchers’ image in-vivo animals. The optical module can be used on the bench for high throughput planar optical imaging, while deep tissue 3D imaging is made possible by moving the module to MILabs’ ultra-high definition CT or Nuclear/CT platform. For the first time, this enables diagnostic CT level image data to correct optical signals for tissue scatter and absorption variations in tissue, thus enabling quantitative 3D/4D optical tomography reconstruction. For further reading, click here.
On the cover…
Researchers at the Department of Nanomedicine and Theranostics of RWTH Aachen University macroscopically investigated biodistributions and target site accumulation of CCPM (Core-crosslinked polymeric micelles). Fluorophore-labeled CCPM were intravenously injected in mice bearing 4T1 triple-negative breast cancer (TNBC) tumors. Their localization at the whole-body, tissue, and cellular level was analyzed using MILabs non-invasive CT-guided 3D fluorescence tomography (FLT/CT) and 2D fluorescence intensity imaging. For further reading, click here.
As used by leading academic institutions and biopharma companies
Researchers at Columbia University published using MILabs’ CT-guided 3D fluorescence tomography (FLT/CT) for drug development. As illustrated, Cy7 labeled mouse albumin (Cy7-ALB) located at different depths within a mouse brain causes wild image intensity changes with planar IVIS, while 3D tomographic MILabs’ FLT/CT delivers quantitative results and excellent localization. After further comparison of FLT/CT with 89Zr PET/CT, they concluded that MILabs’ OI/CT could reliably be used to image glioblastomas. Click here for the publication.
Importance of combining Ultra-high Definition CT with Optical Imaging
High-resolution, low-dose CT imaging is a critical part of MILabs OI/CT Optical Tomography technology. It is essential for correcting optical light scattering and absorption differences, and the diagnostic CT capabilities enable high-resolution angiography of solid tumor growth. Progression to malignancy depends on a complex interaction between tumor cells and the body’s blood vessels. Blood vessels provide the route for delivering most therapeutics with optical reporters to the tumor or oxygen to effectuate therapy. This duality in the tumor microvasculature’s cancer therapy role underscores a dual-modality OI/CT system’s advantages to complement molecular images with intravital images of complex vascular biology. For further reading, click here
International Workshop on Radiobiology of Molecular Radiotherapy
Initially planned in Montpellier in May 2020, the MRT Radiobiology meeting has been converted into a virtual conference on March 17th and 18th, 2021. It’s the first of a series of workshops launched by the European MRT radiobiology working group that will be held in Europe every two years. More information at: https://www.mrtradiobiology.com
Prostate cancer: Lutetium-177 PSMA-SPECT
Eline Ruigrok, et al. of the Erasmus MC, illustrate that the selection of linker composition seems essential in designing novel molecular radiotherapies. A MILabs VECTor/CT system was used for an extensive preclinical evaluation of lutetium-177-labeled PSMA-specific SPECT tracers for prostate cancer radionuclide therapy. For further reading, click here.
MILabs Preclinical Imaging Solutions
Job Openings to support MILabs’ accelerating growth
With a compounded annual growth rate of nearly 50% since 2018, MILabs seeks talented individuals to further scale-up its organization and to strengthen the support of its customers and industry collaborators.